Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled the release of its Q4 and full-year 2024 financial results for Thursday, March 13, 2025, before market opening.
The upcoming announcement will feature an operational update covering key quarterly achievements, recent accomplishments, and financial highlights from 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX), un'azienda farmaceutica specializzata in fase clinica avanzata che si concentra su malattie rare e orfane, ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 13 marzo 2025, prima dell'apertura del mercato.
Il prossimo annuncio includerà un aggiornamento operativo che coprirà i principali risultati trimestrali, le recenti conquiste e i punti salienti finanziari del 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX), una compañía farmacéutica especializada en etapa clínica avanzada que se centra en enfermedades raras y huérfanas, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 13 de marzo de 2025, antes de la apertura del mercado.
El próximo anuncio presentará una actualización operativa que abarcará los logros clave del trimestre, los recientes éxitos y los aspectos destacados financieros de 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX), 희귀 및 고아 질환을 전문으로 하는 후기 임상 단계의 전문 제약 회사는 2025년 3월 13일 목요일, 시장 개장 전에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다.
이번 발표에는 주요 분기 성과, 최근 성과 및 2024년 재무 하이라이트를 포함한 운영 업데이트가 포함될 것입니다.
Quoin Pharmaceuticals (NASDAQ: QNRX), une entreprise pharmaceutique spécialisée en phase clinique avancée se concentrant sur les maladies rares et orphelines, a prévu de publier ses résultats financiers du quatrième trimestre et de l'année complète 2024 le jeudi 13 mars 2025, avant l'ouverture des marchés.
Cette annonce à venir comprendra une mise à jour opérationnelle couvrant les principales réalisations trimestrielles, les succès récents et les points forts financiers de 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein spezialisiertes Pharmaunternehmen in der späten klinischen Phase, das sich auf seltene und Waisenerkrankungen konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 13. März 2025, vor Markteröffnung angesetzt.
Die bevorstehende Ankündigung wird ein operatives Update enthalten, das wichtige vierteljährliche Erfolge, jüngste Errungenschaften und finanzielle Höhepunkte aus 2024 abdeckt.
- None.
- None.
ASHBURN, Va., March 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Thursday, March 13, 2025.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2024.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q4 2024 earnings?
What will be included in Quoin Pharmaceuticals' (QNRX) upcoming earnings release?
What is Quoin Pharmaceuticals' (QNRX) main business focus?
Which stock exchange is Quoin Pharmaceuticals (QNRX) listed on?
